Neurocrine shares rise 8% after hours, INGREZZA forecast raised

Shares rose 8.2% in after-hours trading as of 5:14 p.m. ET, from a regular-session close of $145.58.

Neurocrine Biosciences (NBIX) said on Nov. 2, 2026 that third-quarter revenue rose 41% from a year earlier to $1.12 billion. The company also raised its 2026 forecast for INGREZZA net product sales.

Adjusted earnings per share were $3.29, topping the $1.95 consensus estimate. Revenue came in above the $1.06 billion estimate.

Here’s how the company did:

• Revenue: $1.12 billion vs. $795 million a year earlier, against a $1.06 billion consensus estimate
• Adjusted EPS: $3.29 vs. $2.17 a year earlier, against a $1.95 consensus estimate
• GAAP EPS: $1.96 vs. $2.04 a year earlier
• GAAP net income: $207 million vs. $210 million a year earlier
• Non-GAAP net income: $347 million vs. $222 million a year earlier
• Cash and marketable securities: $790 million at Sept. 30, 2026, vs. $2.54 billion at Dec. 31, 2025

The company said the revenue increase came mainly from higher net product sales, which rose $329 million from a year earlier.

The company’s chief executive gave the quarter’s headline in the release. “Our third quarter performance marks another important milestone in Neurocrine’s evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines,” said Chief Executive Officer Kyle W. Gano, Ph.D.

Segment results

INGREZZA net product sales were $801 million, up 17% from a year earlier. The company said results reflected double-digit volume growth.

CRENESSITY net product sales were $211 million, up 115% from $98 million a year earlier. The company cited steady new patient demand and approximately 80% reimbursement for dispensed prescriptions.

VYKAT XR net product sales were $107 million. The company said sales were driven by steady and consistent patient demand and persistency.

Revenue has risen in each of the last three quarters, from $794.9 million to $959.0 million, according to its SEC filings.

2026 guidance

The company raised its full-year INGREZZA net product sales guidance to $2.9 billion to $2.925 billion, from $2.825 billion to $2.875 billion.

It lowered its GAAP selling, general and administrative expense range to $1.54 billion to $1.56 billion, from $1.575 billion to $1.6 billion. Non-GAAP SG&A guidance fell to $1.29 billion to $1.31 billion, from $1.325 billion to $1.35 billion.

In-process research and development guidance rose to $34 million from $23 million. GAAP and non-GAAP research and development guidance were unchanged.

Costs and other developments

GAAP research and development expense was $352 million, up from $250 million a year earlier. Non-GAAP research and development expense was $317 million, up from $228 million. The company linked the increase to its osavampator Phase 3 program in major depressive disorder and its direclidine Phase 3 program in schizophrenia.

Non-GAAP SG&A expense was $327 million, up from $259 million. The company said the increase reflected continued investment in its commercial organization.

The company reported a $52 million loss from changes in fair values of equity investments, compared with a gain of $31 million a year earlier.

GAAP operating expenses included certain costs tied to the acquisition of Soleno Therapeutics, Inc., which closed in May 2026. Those costs are excluded from non-GAAP operating expenses.

The company said Eiry W. Roberts, M.D., who previously served as Chief Medical Officer and most recently as a Strategic Advisor, has rejoined the executive management team as Chief Medical Officer. The company also said it will host an R&D Day in New York on Dec. 15, 2026.